Neos Therapeutics Inc. appointed Thomas P. McDonnell, to the role of Chief Commercial Officer, effective immediately. Prior to joining Neos, Mr. McDonnell spent 10 years with Shire most recently as Vice President of US Marketing in the Neuroscience Business Unit from December 2013 to March 2015. In this role, he led the US Product Strategy Team responsible for the commercialization of Vyvanse and Intuniv into the ADHD market.

From August 2012 to November 2013, he was Vice President, General Manager of Adult Psychiatry and led the product strategy team for all commercial and clinical development of Vyvanse in Major Depressive Disorder and Binge Eating Disorder. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR.